‘Amazing’ results with new breast cancer drug

525266

Sumary of ‘Amazing’ results with new breast cancer drug:

  • Women with incurable breast cancer have been thrown fresh hope thanks to a ‘mind-blowing’ new drug that holds the disease at bay for more than twice as long as previous treatments..
  • an antibody that helps the immune system find cancer cells and a fighter molecule, which enters the cancer cells and destroy them..
  • Professor Peter Schmid of the Barts Cancer Centre and a researcher involved in the development of Enhertu, said:.
  • It is succeeding where all other treatments seem to fail, because over time, cancer cells adapt to hide from the drugs..
  • Not only does this one work, it continues to work for a long time’ This two-pronged attack leads to dramatic tumour shrinkage in two-thirds of patients given it, compared to just a third having standard treatment, according to the latest trial results..
  • ‘This drug is displaying mind-blowing activity in patients for whom the outcome is usually pretty poor,’ says Peter Schmid, professor of cancer medicine at the Barts Cancer Centre and one of the researchers of the drug..
  • ‘It is succeeding where all other treatments seem to fail, because over time, cancer cells adapt to hide from the drugs..
  • Not only does this one work, it continues to work for a long time.’ About 55,000 Britons are diagnosed with breast cancer every year, mostly women aged over 50..
  • Treatments mean the outlook for most patients is positive, with more than three-quarters of women surviving at least ten years after diagnosis..
  • But one in five patients have a type of breast cancer that produces excess amounts of a protein involved in cell growth, called HER2..
  • In up to a fifth of HER2 positive (written HER2+) patients, even if the cancer is initially eradicated, tumours recur – either in the breast or elsewhere in the body..
  • There are drugs and other treatments for these patients but the effects are short-lived and many run out of options within a few months..
  • But now, if we have a drug that can control the disease for two years, we imagine it will significantly extend survival, too.’ Side effects occur at a similar rate to existing treatments, with roughly a third of the test patients experiencing complications such as lung infections..
  • Enhertu is said to have a unique ability to draw the active compounds directly into the nucleus of the cancer cell, which contains its DNA, to destroy it This also minimises the impact of the drug on surrounding, healthy cells, reducing the severity of side effects..
  • Prof Schmid says the drug could soon be licensed for use earlier on in treatment of HER2+ breast cancer – not just when patients have run out of all other options…

Want to know more click here go to source.

From -
Close
Generic selectors
Exact matches only
Search in title
Search in content

Site Language


By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close